An observational study in Siewert Type II Adenocarcinoma of Esophagogastric Junction, sponsored by University of Bologna. Completed at 2 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by University of Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Esophageal Neoplasms with a site in Italy — 17 open to participants now, 23 under way, 4 of them phase 3. Esophageal Neoplasms · Italy.
Among the 50 studies in Esophageal Neoplasms with a site in Italy, this one is the 10th largest by enrollment of the 12 observational ones that give a count, is the only one that started in 2007, is one of 12 observational ones, and was the 10th registered.
1,873 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →17 of the 50 studies in Esophageal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Australia and 21 more countries
Ages 18+
University Hospital, Antwerp · Sites in Italy, Belgium, Denmark and 3 more countries
Ages 18+
Bayer · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Brazil and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 12 · Phase 3 7
First in 1992; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is below the median of 200 across 432 observational studies indexed under Esophageal Neoplasms.
Median enrollment 205 across the 38 interventional studies, 2,000 across the 12 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 50 have an industry lead sponsor. The 10 most frequent:
University of Bologna is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
University of Bologna has 1 study filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Esophageal Neoplasms with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06115629Phase 3University of Dublin, Trinity CollegeSurveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial | 2026-11 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT05319730Merck Sharp & Dohme LLCA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | 2027-06-11 |
| NCT06172478Daiichi SankyoA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Esophageal Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In Siewert type II adenocarcinoma, the relationship between adenocarcinoma sub types and survival, histologic/biologic patterns related to the presence/absence of gastric greater curvature metastases, were investigated.
In order to achieve further data on the biological patterns of intestinal and diffuse subtypes of esophageal adenocarcinoma (Lauren's classification), on the frequency of gastric greater curvature nodal stations and on the clinical relevance, in terms of prognosis and survival, of these parameters, a Siewert type II case series of Siewert type II adenocarcinomas, submitted to primary (no neoadjuvant therapy) surgical, studied, operated upon and followed up, were analysed. According to histologic patterns, cases were ordered in intestinal and diffuse adenocarcinoma sub types (Lauren's classification)and distinguished in Barret's, cardiopyloric, gastric types.
One hundred fifty four Siewert type II cases were enrolled: 124 men (80.5%), 30 women (19.5%), median age 65.5 (interquartile range 58-71); Intestinal type 91 (59%) and Diffuse type 63 (41%).
Inclusion Criteria:
Siewert type II adenocarcinoma > 18 year submitted to primary surgery
Exclusion Criteria: Siewert type II adenocarcinoma submitted to therapy.
Siewert type I adenocarcinoma. Siewert type III adenocarcinoma Squamous Carcinoma
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification \[39\] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
Also known as: Distal Esophagectomy
Survival
5 year survival between intestinal and diffuse types (Lauren's classification) of Siewert type II adenocarcinoma after primary surgery,
Time frame: 5 years
Frequency of gastric greater curvature lymph nodes metastases in Siewert II adenocarcinoma
Frequency of gastric greater curvature lymph nodes metastases and survival
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2007 to primary completion in Jun 2017, 125 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.